← Human Trials & Peer-Reviewed Studies
The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion
Plain-language guide to PMID 9024260 (1997): placebo-controlled randomized controlled trial study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).
Key Facts
- PMID
- 9024260
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 1997
- Study type
- Randomized Controlled Trial
- Authors
- Van den Berghe G et al. (11 authors)
- DOI
- 10.1210/jcem.82.2.3736
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).
In this condition, GH is readily released in response to a bolus of GHRH and GH-releasing peptide-2 (GHRP-2) and, paradoxically, to TRH.
The researchers further explored the altered somatotropic axis and cortisol secretion in critical illness by examining the effects of continuous GHRH and/or GHRP-2 infusion.
Who Took Part
PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
In design terms this was a randomized, placebo-controlled and crossover study.
Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.
Some participants received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.
In the crossover set-up each of the participants took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.
What Was Measured
PubMed files the paper under topics including Critical Care, Critical Illness, Drug Combinations, Entropy, Growth Hormone-Releasing Hormone, Human Growth Hormone and Hydrocortisone.
What This Means in Plain Language
The paper is a randomized, placebo-controlled and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).
The publication is from 1997 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.
Our Notes on the Compounds
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.
Related Pages
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library
- GHRH (Growth Hormone-Releasing Hormone) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.